NCT05061030View on ClinicalTrials.gov

Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

September 30, 2028

Study Completion Date

December 31, 2028

Conditions
Type1diabetes
Interventions
BIOLOGICAL

the ATMP Protrans

Protrans consists of Wharton's jelly derived mesenchymal stromal cells

Trial Locations (1)

75185

RECRUITING

Uppsala University Hospital, Uppsala

All Listed Sponsors
lead

Uppsala University Hospital

OTHER